8,11-Dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: Synthesis and antitumor evaluation

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3494-3501

  Stefańska, Barbara ^a   Dzieduszycka, Maria ^a   Bontemps Gracz, Maria M ^a   Borowski, Edward ^a   Martelli, Sante ^b   Supino, Rosanna ^c   Pratesi, Graziella ^c   De Cesare, MichelAndrea ^c   Zunino, Franco ^c   Kuśnierczyk, Halina ^d   Radzikowski, Czesław ^d  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF CAMERINO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

8,11 DIHYDROXY 6 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 7H BENZO[E]PERIMIDIN 7 ONE HYDROCHLORIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; MITOXANTRONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN;

ANIMALS; ANTHRACENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA P388; MICE; MITOXANTRONE; QUINAZOLINES; TUMOR CELLS, CULTURED;

EID: 0033539129     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980682p     Document Type: Article

References (38)

1. (a) Murdock, K. C.; Child, R. G.; Fabio, P. F.; Angier, R. B.; Wallace, R. E.; Durr, F. E.; Citarella, R. V. Antitumor Agents 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J. Med. Chem. 1979, 22, 1024-1030.
2. (b) Cheng, C.; Zee-Cheng, R. K. Y. The Design, Synthesis and Development of a New Class of Potent Antineoplastic Anthraquinones. Prog. Med. Chem. 1983, 20, 83-118.
3. (c) Shenkenberg, T. D.; Von Hoff, D. D. Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity. Ann. Int. Med. 1986, 105, 67-81.
4. (d) Koeller, J.; Eble, M. Mitoxantrone: A Novel Anthracycline Derivative. Clin. Pharm. 1988, 7, 574-581.
5. (e) Faulds, D.; Balfour, J. A.; Chrisp, P.; Langtry, H. D. Mitoxantrone. A Review of its Pharmacodinamic and Pharmacokinetic Properties, and Therapeutic Potential in the Chemotherapy of Cancer. Drugs 1991, 41, 400-449.
6. (a) Tumminello, F. M.; Leto, G.; Gebbia, N.; Gebbia, V.; Russo, A.; Rausa, L. Acute Myocardial Effects of Mitoxantrone in the Rabbit. Cancer Treat. Rep. 1987, 71, 529-531.
7. (b) Perkins, W. E.; Schroeder, R. L.; Carrano, R. A.; Imondi, A. R. Myocardial Effects of Mitoxantrone and Doxorubicin in the Mouse and Guinea Pig. Cancer Treat. Rep. 1984, 68, 841-847.
8. (a) Selassie, C. D.; Hansch, C.; Khwaja, T. A. Structure - Activity Relationships of Antineoplastic Agents in Multidrug Resistance. J. Med. Chem. 1990, 33, 1914-1919.
9. (b) Bradley, G.; Juranka, P. F.; Ling, V. Mechanism of Multidrug Resistance. Biochim. Biophys. Acta 1988, 948, 87-128.
10. (c) Endicott, J. A.; Ling, V. The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
11. Krapcho, A. P.; Getahun, Z.; Avery, K. L., Jr.; Vargas, K. J.; Hacker, M. P.; Spinelli, S.; Pezzoni, G.; Manzotti, C. Synthesis and Antitumor Evaluation of Symmetrically and Unsymmetrically Substituted 1,4-Bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-Bis[(aminoalkyl)amino]-5,8-dihydroxy-anthracene-9,10-diones. J. Med. Chem. 1991, 34, 2373-2380.
12. Krapcho, A. P.; Petry, M. E.; Getahun, Z.; Landi, J. J., Jr.; Stallman, J.; Polsenberg, J. F.; Gallagher, C. E.; Maresch, M. J.; Hacker, M. P.; Giuliani F. C.; Beggolin, G.; Pezzoni, G.; Menta, E.; Manzotti, C.; Oliva, A.; Spinelli, S.; Tognella, S. 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A Novel Class of Chromophore-Modified Antitumor Anthracene-9,10-diones: Synthesis and Antitumor Evaluation. J. Med. Chem. 1994, 37, 828-837.
13. Gandolfi, C. A.; Beggiolin, G.; Menta, E.; Palumbo, M.; Sissi, C.; Spinelli, S.; Johnson, F. Chromophore-Modified Antitumor Anthracenediones: Synthesis, DNA Binding, and Cytotoxic Acivity of 1,4-Bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones. J. Med. Chem. 1995, 38, 526-536.
14. (a) Showalter, H. D. H.; Johnson, J. L.; Hoftiezer, J. M.; Turner, W. R.; Werbel, L. M.; Leopold, W. R.; Shillis, J. L.; Jackson, R. C.; Elslager, E. F. Anthrapyrazole Anticancer Agents. Synthesis and Structure-Activity Relationships Against Murine Leukemias. J. Med. Chem. 1987, 30, 121-131.
15. (b) Showalter, H. D. H.; Werbel, L. M.; Leopold, W. R.; Fry, D. W.; Klohs, W. D.; Jackson, R. C. Design, Tumor Biology, and Biochemical Pharmacology of Anthrapyrazoles. In Anthracycline and Anthracenedione-based Anticancer Agents; Lown, J. W., Ed.; Elsevier Science Publishers B.V.: Amsterdam, The Netherlands, 1988; pp 201-243.
16. (c) Klohs, W. D.; Steinkampf, R. W.; Havlick, M. J.; Jackson, R. C. Resistance to Anthrapyrazoles and Anthracyclines in Multidrug-resistant P388 Murine Leukemia Cells: Reversal by calcium Blockers and Calmodulin Antagonists. Cancer Res. 1986, 46, 4352-4356.
17. Krapcho, A. P.; Menta, E.; Oliva, A.; Di Domenico, R.; Fiocchi, L.; Maresch, M. E.; Gallagher, C. E.; Hacker, M. P.; Beggiolin, G.; Giuliani, F. C.; Pezzoni, G.; Spinelli, S. Synthesis and Antitumor Evaluation of 2,5-Disubstituted-Indazolo[4,3-gh]isoquinolin-6(2H)-ones (9-Aza-anthrapyrazoles). J. Med. Chem. 1998, 41, 5429-5444.
18. (a) Stefańska, B. Unpublished data.
19. (b) Bontemps-Gracz, M. M.; Stefańska, B.; Dzieduszycka, M.; Borowski, E.; Antonini, I.; Martelli, S.; Supino, R.; Zunino, F. Biological Characterization of Novel Anthracenedione Analogues and Related Compounds with Fused Heterocyclic Rings. Effectiveness against Multidrug Resistant Tumor Cell Lines. Multidyscyplinarna Konferencja Nauki o Leku (Multidisciplinary Conference of Medicinal Science), March 3-5, 1999, Muszyna, Poland; Abstract Book, Abstract P-80.
20. (a) Cholody, W. M.; Martelli, S.; Paradziej-Lukowicz, J.; Konopa, J. 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridine-6-ones as a Novel Class of Antineoplastic Agents: Synthesis and Biologcal Activity. J. Med. Chem. 1990, 33, 49-52.
21. (b) Berger, B.; Marquardt, H.; Westendorf, J. Pharmacological and Toxicological Aspects of New Imidazoacridinone Antitumor Agents. Cancer Res. 1996, 56, 2094-2104.
22. (a) Chotody, W. M.; Martelli, S.; Konopa, J. 8-Substituted 5-[(Aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acidin-6-ones as Potential Antineoplastic Agents. Synthesis and Biological Activity. J. Med. Chem. 1990, 33, 2852-2856.
23. (b) Składanowski, A. Unpublished data.
24. Sugaya, T.; Mimura, Y.; Shida, Y.; Osawa, Y.; Matsukuma, I.; Ikeda, S.; Akinaga, S.; Morimoto, M.; Ashizawa, T.; Okabe, M.; Ohno, H.; Gomi, K.; Kasai, M. 6H-Pyrazolo[4,5,1-de]acridin-6-ones as a Novel Class of Antitumor Agents. Synthesis and Biological Activity. J. Med. Chem. 1994, 37, 1028-1032.
25. Antonini, I.; Cola, D.; Polucci, P.; Bontemps-Gracz, M.; Borowski, E.; Martelli, S. Synthesis of (Dialkylamino)alkyl-disubstituted Pyrimido[5,6,1-de]acridines, a Novel Group of Anticancer Agents Active on a Multidrug Resistant Cell Line. J. Med. Chem. 1995, 38, 3282-3286.
26. Stefańska, B.; Dzieduszycka, M.; Martelli, S.; Tarasiuk, J.; Bontemps-Gracz, M.; Borowski, E. 6-[(Aminoalkyl)amino]-Substituted 7H-Benzo[e]perimidin-7-ones as Novel Antineoplastic Agents. Synthesis and Biological Evaluation. J. Med. Chem. 1993, 36, 38-41.
27. Tarasiuk, J.; Garnier-Suillerot, A.; Stefańska, B.; Borowski, E. The Essential Role of Anthraquinones as Substrates for NADH Dehydrogenase in Their Redox Cycling Activity. Anti-Cancer Drug Des. 1992, 7, 329-340.
28. Chołody, W. M.; Martelli, S.; Konopa, J. Chromophore-Modified Antineoplastic Imidazoacridinones. Synthesis and Activity Against Murine Leukemias. J. Med. Chem. 1992, 35, 378-382.
29. Kato, N.; Sugaya, T.; Mimura, T.; Ikuta, M.; Kato, S.; Kuge, Y.; Tomioka, S.; Kasai, M. Facile and Efficient Synthesis of 7,10-Dihydroxy-6H-pyrazolo[4,5,1-de]acridin-6-one via Hypervalent Iodine Oxidation. Synthesis 1997, 625-627.
30. Dzieduszycka, M.; Stefańska, B.; Borowski, E. Synthesis of 1,4 Diamino-5,8-dihydroxy-9,10-anthracenedione via Gabriel Reaction. Pol. J. Chem. 1994, 68, 1669-1671.
31. Showalter, H. D. H.; Turner, W. R. Anticancer Anthrapyrazoles. The Synthesis of 2-Substituted 5-Nitro and 5-Aminoanthra[1,9-cd]pyrazol-6(2H)-ones. J. Heterocycl. Chem. 1993, 30, 493-496.
32. Matuszyk, J.; Kuœnierczyk, H.; Radzikowski, C. Biological Evaluation of Mitoxantrone Dihydrochloride Synthesized by a New Methodol. I. Acute Toxicity and Antitumor Activity in Mouse Transplantable Tumor Systems. Arch. Immunol. Ther. Exp. 1989, 37, 77-87.
33. Tkaczyk-Gobis, K.; Tarasiuk, J.; Stefańska, B.; Dzieduszycka, M.; Seksek, O.; Borowski, E.; Garnier-Suillerot, A. Mechanism of Action of Benzoperimidines Active on Multidrug Resistant Tumor Cell Lines. Multidyscyplinarna Konferencja Nauki o Leku (Multidisciplinary Conference of Medicinal Science), March 3-5, 1999, Muszyna, Poland; Abstract Book, Abstract P-81.
34. Tarasiuk, J.; Tkaczyk-Gobis, K.; Stefańska, B.; Dzieduszycka, M.; Priebe, W.; Martelli, S.; Borowski, E. The Role of Structural Factors of Anthraquinones and Their Heteroatomic Analogues in NADH Dehydrogenase Catalysed Oxygen Radical Formation. Anti-Cancer Drug Des. 1998, 13, 923-939.
35. Bontemps-Gracz, M.; Milewski, S.; Borowski, E. The Influence of L-Norvalyl-N3-4-methoxyfumaroyl-L-2,3-diaminopropanoic Acid, an Antifungal Agent, on Mammalian Cells in Tissue Culture. Acta Biochim. Pol. 1991, 38, 229-239.
36. (a) Geran, R. I.; Greenberg, N. H.; Macdonald, M. M.; Schumacher, A. M.; Abbott, B. J. Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems. Cancer Chemother. Rep. 1972, 3, 1-88.
37. (b) In vivo Cancer Models; NIH Publication No. 84-2635, 1984; p 27.
38. Grandi, M.; Geroni, C.; Giuliani, F. C. Isolation and Characterization of a Human Colon Adenocarcinoma Cell Line Resistant to Doxorubicin. Br. J. Cancer 1986, 54, 515-518.